The past decade has been a brutal reminder that infectious diseases are not a problem of the past. From SARS-CoV-2 to mpox, from Ebola outbreaks in Central Africa to the resurgence of polio in regions that had eradicated it, the world has seen how fragile public health systems can trigger global crises in a matter of weeks. Today, in 2026, the question is no longer whether a new epidemic will emerge, but how prepared we are to detect, contain, and respond without collapsing the rest of the economy.
The World Health Organization estimates that 60% of international health emergencies in the last five years originated in zoonoses—diseases that jump from animals to humans—many linked to deforestation and wildlife trade.
Epidemiological surveillance: the first shield
Detecting an outbreak early is the difference between a local problem and a pandemic. Countries have invested in laboratory networks, early warning systems, and digital platforms that cross-reference data from hospitals, pharmacies, and wastewater. However, the gap between wealthy and poor nations remains enormous. While Europe and North America have genomic sequencing systems capable of identifying a pathogen in hours, large parts of Africa, Asia, and Latin America lack even basic laboratories. Technical cooperation and data sharing, often hindered by political mistrust, remain unfinished business.
What is a zoonosis?
An infectious disease transmitted from animals to humans. Examples: COVID-19, Ebola, monkeypox, bird flu. Its emergence is linked to habitat destruction and increasing human-animal contact.
State response: between preparedness and improvisation
When an outbreak is declared, governments must activate protocols ranging from case isolation to border closures. But the experience of recent years has shown that the key lies in flexibility and in maintaining essential services (education, transport, regular healthcare) while deploying a health response. Countries like Thailand, Rwanda, and Chile have been noted for their rapid reaction to bird flu and dengue outbreaks, combining clear communication campaigns with investment in primary care. In contrast, nations with fragmented or politicized systems have seen epidemics turn into political crises.
Access to medicines and vaccines: the last mile
One of the greatest challenges remains the equitable distribution of treatments and vaccines. During the COVID-19 pandemic, the COVAX mechanism showed that global solidarity is possible, but also that wealthy countries hoard doses when domestic pressure rises. Today, with new vaccines against malaria and dengue in deployment phases, and with more effective antiviral therapies, the logistics of the cold chain and local production capacity in low- and middle-income countries are the bottleneck. Without technology transfer and sustained funding, the right to health remains a geographical privilege.
It is estimated that 30% of vaccines produced worldwide are lost due to cold chain failures, especially in regions with poor electrical infrastructure.
What does this mean for the world?
The hardest lesson of the last decade is that public health is not an expense, but an investment in global stability. Every dollar invested in surveillance and preparedness saves dozens in emergency response and lost productivity. International cooperation, through bodies like the WHO, development banks, and bilateral agreements, must prioritize strengthening health systems in the most vulnerable countries. In a world where an outbreak in a remote village can reach any capital within 36 hours, global health is, simply put, a matter of collective security.